MPG.eBooks - Staff View: CADTH Canadian Drug Expert Committee recommendation (final): Sebelipase alfa (Kanuma -- Alexion Pharmaceuticals, Inc.) indication : lysosomal acid lipase deficiency

Read Now

Bibliographic Details
Corporate Authors:	CADTH Canadian Drug Expert Committee, Canadian Agency for Drugs and Technologies in Health
Format:	eBook
Language:	English
Published:	Ottawa (ON) Canadian Agency for Drugs and Technologies in Health September 28, 2018, 2018
Edition:	Version 1.0
Series:	CADTH common drug review
Online Access:	https://www.ncbi.nlm.nih.gov/books/NBK538940
Collection:	National Center for Biotechnology Information - Collection details see MPG.ReNa


LEADER	01029nam a2200241 u 4500
001	EB002000931
003	EBX01000000000000001163832
005	00000000000000.0
007	tu\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
008	210907 r \|\|\| eng
245	0	0	\|a CADTH Canadian Drug Expert Committee recommendation (final): Sebelipase alfa (Kanuma -- Alexion Pharmaceuticals, Inc.) indication : lysosomal acid lipase deficiency \|h Elektronische Ressource
246	3	1	\|a Sebelipase alfa (Kanuma)
246	3	1	\|a lysosomal acid lipase deficiency
250			\|a Version 1.0
260			\|a Ottawa (ON) \|b Canadian Agency for Drugs and Technologies in Health \|c September 28, 2018, 2018
300			\|a 1 PDF file (9 pages)
710	2		\|a CADTH Canadian Drug Expert Committee
710	2		\|a Canadian Agency for Drugs and Technologies in Health
041	0	7	\|a eng \|2 ISO 639-2
989			\|b NCBI \|a National Center for Biotechnology Information
490	0		\|a CADTH common drug review
856	4	0	\|u https://www.ncbi.nlm.nih.gov/books/NBK538940 \|3 Volltext
082	0		\|a 610